| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tetrandrine (also called Fanchinine; Sinomenine A; d-tetrandrine; formerly NSC-77037), a bis-benzylisoquinoline alkaloid derived from Stephania tetrandra, is a novel and potent calcium channel blocker which inhibits voltage-gated Ca2+ current (ICa) and Ca2+-activated K+ current. Tetrandrine inhibits the L-type calcium channels (IC50 = 0.3-8 µM) and T-type calcium channels (IC50 = 2.5-20 µM). Moreover, the Ca2+-activated K+ channel (Kd=0.2 µM) is strongly blocked by it. In isolated nerve terminals of the rat neurohypophysis, tetrandrine inhibits voltage-gated Ca2+ currents with an IC50 of 10.1 mM. With an IC50 of 0.21 mM, tetrandrine is a high-affinity blocker of the type II, maxi-Ca(2+)-activated K+ channel of the rat neurohypophysial terminals.
| Targets |
Ca2+ current; K+ current
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay |
The effects of tetrandrine, a bis-benzyl-isoquinoline alkaloid, on voltage-gated Ca2+ currents (ICa) and on Ca(2+)-activated K+ current (IK(Ca)) and channels in isolated nerve terminals of the rat neurohypophysis were investigated using patch-clamp techniques. The non-inactivating component of ICa was inhibited by external tetrandrine in a voltage- and dose-dependent manner, with an IC50 = 10.1 microM. IK(Ca) was elicited by depolarizations when approximately 10 microM Ca2+ was present on the cytoplasmic side. Only externally applied tetrandrine, at 1 microM, decreased the amplitude of IK(Ca), whereas the fast inward Na+ current and transient outward K+ current were not affected. Tetrandrine, applied to the extracellular side of outside-out patches excised from the nerve terminals, induced frequent and short closures of single type II, maxi-Ca(2+)-activated K+ channels. Tetrandrine decreased the channel-open probability, within bursts, with an IC50 = 0.21 microM. Kinetic analysis of the channel activity showed that the open-time constant decreased linearly with increasing tetrandrine concentrations (0.01-3 microM), giving an association rate constant of 8.8 x 10(8) M-1 s-1, whereas the arithmetic mean closed time did not change, giving a dissociation rate constant of 136.6 s-1. These results show that tetrandrine is a high-affinity blocker of the type II, maxi-Ca(2+)-activated K+ channel of the rat neurohypophysial terminals[1].
|
||
| Cell Assay |
In a 96-well plate, Huh7, HCCLM9, and Hep3B cells are seeded at a density of 5 × 103 cells/well. For twenty-four hours, the cells are exposed to Tetrandrine (NSC-77037) at the indicated concentrations (0–4 μM). After staining the cells for one to two hours with 20 μL of MTS, the plates are read at 490 nm using a BioTek ELx800[2].
Background: Tetrandrine is a bisbenzylisoquinoline alkaloid isolated from the Chinese medicinal herb Stephania tetrandra S. Moore. We previously demonstrated that tetrandrine exhibits potent antitumor effects in many types of cancer cells. In this study, we investigated the effects of tetrandrine on human hepatocellular carcinoma (HCC) metastasis. Methods: The invasion and migration effects were evaluated via wound healing and transwell assays. Immunofluorescence and western blotting analyses were used to investigate the levels of epithelial-mesenchymal transition (EMT)-related protein. A metastasis model was established to investigate the inhibitory effect of tetrandrine on hepatocellular carcinoma metastasis in vivo. Results: Tetrandrine inhibits HCC invasion and migration by preventing cell EMT. The underlying mechanism was closely associated with tetrandrine-induced human liver cell autophagy, which inhibits Wnt/β-catenin pathway activity and decreases metastatic tumor antigen 1 (MTA1) expression to modulate cancer cell metastasis. Conclusion: Our findings demonstrate, for the first time, that tetrandrine plays a significant role in the inhibition of human hepatocellular carcinoma metastasis and provide novel insights into the application of tetrandrine in clinical HCC treatment.[2] |
||
| Animal Protocol |
|
||
| Toxicity/Toxicokinetics |
mouse LD50 intraperitoneal 41300 ug/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Zhongliu Yanjiu Cancer Review, Yu, R., et al., eds., Shanghai Science/Technology Publisher,Peop. Rep. China, 1994, -(216), 1994
mouse LD50 intravenous 37500 ug/kg Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal., 25(39), 1990 cat LDLo intravenous 40 mg/kg BEHAVIORAL: TREMOR; CARDIAC: OTHER CHANGES; LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Zhongcaoyao. Chinese Traditional and Herbal Medicine., 25(610), 1994 rabbit LDLo intravenous 15 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD; CARDIAC: OTHER CHANGES; LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal., 25(39), 1990 |
||
| References |
|
||
| Additional Infomation |
(+)-Tetrandrine is a member of isoquinolines and a bisbenzylisoquinoline alkaloid.
Tetrandrine has been reported in Stephania tetrandra, Cyclea barbata, and other organisms with data available. Tetrandrine is a natural, bis-benzylisoquinoline alkaloid isolated from the root of the plant Radix stephania tetrandrae. Tetrandrine non-selectively inhibits calcium channel activity and induces G1 blockade of the G1 phase of the cell cycle and apoptosis in various cell types, resulting in immunosuppressive, anti-proliferative and free radical scavenging effects. This agent also increases glucose utilization by enhancing hepatocyte glycogen synthesis, resulting in the lowering of plasma glucose. (NCI04) |
| Molecular Formula |
C38H42N2O6
|
|
|---|---|---|
| Molecular Weight |
622.75
|
|
| Exact Mass |
622.304
|
|
| Elemental Analysis |
C, 73.29; H, 6.80; N, 4.50; O, 15.41
|
|
| CAS # |
518-34-3
|
|
| Related CAS # |
|
|
| PubChem CID |
73078
|
|
| Appearance |
Solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
710.5±60.0 °C at 760 mmHg
|
|
| Melting Point |
219-222ºC
|
|
| Flash Point |
175.8±30.1 °C
|
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
|
| Index of Refraction |
1.586
|
|
| LogP |
3.55
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
46
|
|
| Complexity |
979
|
|
| Defined Atom Stereocenter Count |
2
|
|
| SMILES |
COC1=CC(CCN(C)[C@@]2([H])CC3=CC(O4)=C(OC)C=C3)=C2C(OC5=C(OC)C=C6C([C@]([H])(CC7=CC=C4C=C7)N(C)CC6)=C5)=C1OC
|
|
| InChi Key |
WVTKBKWTSCPRNU-KYJUHHDHSA-N
|
|
| InChi Code |
InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30-/m0/s1
|
|
| Chemical Name |
(1S,14S)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (16.06 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6058 mL | 8.0289 mL | 16.0578 mL | |
| 5 mM | 0.3212 mL | 1.6058 mL | 3.2116 mL | |
| 10 mM | 0.1606 mL | 0.8029 mL | 1.6058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05697029 | Not yet recruiting | Drug: Tetrandrine | COVID-19 | Peking University Third Hospital |
December 31, 2023 | Phase 4 |
| NCT05245448 | Not yet recruiting | Drug: Tetrandrine Drug: Placebo |
Rheumatoid Arthritis | Peking University People's Hospital |
February 22, 2022 | Not Applicable |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
